Literature DB >> 27368062

Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans.

Chul-Hee Kim1, Hong-Kyu Kim2, Eun-Hee Kim3, Sung-Jin Bae3, Jaewon Choe3, Joong-Yeol Park4.   

Abstract

AIMS: To examine the abilities of HbA1c and fasting plasma glucose (FPG) criteria predicting 5-year progression rate to diabetes in Korean adults with prediabetes.
METHODS: Participants included 17,971 Koreans (aged 20-79years) who underwent routine medical check-ups at a mean interval of 5.2years (3.1-6.7years). Prediabetes was defined as FPG 5.6-6.9mmol/l or HbA1c 5.7-6.4% (39-46mmol/mol). Incident diabetes was defined as FPG⩾7.0mmol/l, HbA1c⩾6.5% (48mmol/mol), or initiation of antidiabetic medications.
RESULTS: At baseline, the prevalence of prediabetes was 30.6% (n=5495) by FPG and 20.4% (n=3664) by HbA1c criteria. The 5-year progression rate to diabetes was significantly higher in prediabetes identified by HbA1c than by FPG tests (14.7% vs. 10.4%, P<0.001). Of individuals diagnosed with prediabetes by only one test, those by HbA1c alone had a higher risk of progression to diabetes than those diagnosed by FPG alone (6.0% vs. 3.9%, P<0.001). Receiver operating characteristic curve analysis showed that area under the curve was greater for HbA1c (0.855, 95% CI 0.840-0.870) than for FPG (0.830, 0.813-0.846) (P=0.016). After adjustment for conventional risk factors, the odds ratio (OR) of developing diabetes was higher in participants with prediabetes identified by HbA1c (OR 9.91, 8.24-11.9) than by FPG (OR 7.29, 5.97-8.89) (P=0.026).
CONCLUSIONS: Although fewer individuals with prediabetes were identified by HbA1c than by FPG criteria, the ability to predict progression to diabetes was stronger for HbA1c than for FPG in Koreans.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Diabetes risk; Fasting plasma glucose; HbA1c; Prediabetes

Mesh:

Substances:

Year:  2016        PMID: 27368062     DOI: 10.1016/j.diabres.2016.06.009

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

1.  Association of plasma PCB levels and HbA1c concentration in Iran.

Authors:  Sahar Eftekhari; Omid Aminian; Zeinab Moinfar; Thomas Schettgen; Andrea Kaifie; Michael Felten; Thomas Kraus; André Esser
Journal:  J Occup Med Toxicol       Date:  2018-05-31       Impact factor: 2.646

2.  Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study.

Authors:  Masoud Mirzaei; Masoud Rahmaninan; Mohsen Mirzaei; Azadeh Nadjarzadeh; Abbas Ali Dehghani Tafti
Journal:  BMC Public Health       Date:  2020-02-03       Impact factor: 3.295

3.  Plasma HbA1c in the investigation of suspected heart failure in general practice: An audit of the 2018 NICE guidelines update.

Authors:  Theodoros Paschalis; Carol Jones
Journal:  J Family Med Prim Care       Date:  2020-02-28

4.  Cardiometabolic risk factors in Thai individuals with prediabetes treated in a high-risk, prevention clinic: Unexpected relationship between high-density lipoprotein cholesterol and glycemia in men.

Authors:  Weerachai Srivanichakorn; Ian F Godsland; Chaiwat Washirasaksiri; Pochamana Phisalprapa; Phunchai Charatcharoenwitthaya; Pornpoj Pramyothin; Tullaya Sitasuwan; Lukana Preechasuk; Robert Elkeles; K George Mm Alberti; Desmond G Johnston; Nick S Oliver
Journal:  J Diabetes Investig       Date:  2018-11-30       Impact factor: 4.232

5.  Lifestyle and Progression to Type 2 Diabetes in a Cohort of Workers with Prediabetes.

Authors:  Miquel Bennasar-Veny; Sergio Fresneda; Arturo López-González; Carla Busquets-Cortés; Antoni Aguiló; Aina M Yañez
Journal:  Nutrients       Date:  2020-05-25       Impact factor: 5.717

6.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.